Player FM - Internet Radio Done Right
Checked 7d ago
Dodano seven lat temu
Konten disediakan oleh Audioboom and Not So Different: a Podcast from The Center for Biosimilars. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Audioboom and Not So Different: a Podcast from The Center for Biosimilars atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !
Offline dengan aplikasi Player FM !
Not So Different: A Podcast from The Center for Biosimilars
Tandai semua (belum/sudah) diputar ...
Manage series 2161808
Konten disediakan oleh Audioboom and Not So Different: a Podcast from The Center for Biosimilars. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Audioboom and Not So Different: a Podcast from The Center for Biosimilars atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
"Not So Different," a podcast from The Center for Biosimilars, brings you expert viewpoints from physicians, pharmacists, patients, developers, and other stakeholders in the complex world of biosimilar therapies.
…
continue reading
153 episode
Tandai semua (belum/sudah) diputar ...
Manage series 2161808
Konten disediakan oleh Audioboom and Not So Different: a Podcast from The Center for Biosimilars. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Audioboom and Not So Different: a Podcast from The Center for Biosimilars atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
"Not So Different," a podcast from The Center for Biosimilars, brings you expert viewpoints from physicians, pharmacists, patients, developers, and other stakeholders in the complex world of biosimilar therapies.
…
continue reading
153 episode
所有剧集
×![Artwork](/static/images/128pixel.png)
1 S6 Ep42: Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals 14:17
14:17
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai14:17![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show notes 1. Jeremias S. A banner year for biosimilars: The 19 FDA approvals from 2024. The Center for Biosimilars. January 21, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/a-banner-year-for-biosimilars-the-18-fda-approvals-from-2024 2. Jeremias S. FDA approves Celltrion's Avtozma as third tocilizumab biosimilar. The Center for Biosimilars. January 31, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/fda-approves-celltrion-s-avtozma-as-third-tocilizumab-biosimilar 3. Jeremias S. Senators introduce bipartisan legislation to protect skinny labeling. The Center for Biosimilars. January 2, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/senators-introduce-bipartisan-legislation-to-protect-skinny-labeling 4. Jeremias S. FTC releases second report on PBMs meddling in generic drug markets. The Center for Biosimilars. January 19, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/ftc-releases-second-report-on-pbms-meddling-in-generic-drug-markets 5. Santoro C. Earlier patent litigation could accelerate US biosimilar market entry. The Center for Biosimilars. January 9, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/earlier-patent-litigation-could-accelerate-us-biosimilar-market-entry 6. Jeremias S. Welcome Wezlana: the first Stelara biosimilar to launch in the US. The Center for Biosimilars. January 31, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/welcome-wezlana-the-first-stelara-biosimilar-to-launch-in-the-us 7. Jeremias S, Chambers JD. The banking of biosimilars: insights from a leading health economist. The Center for Biosimilars. February 4, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/the-banking-of-biosimilars-insights-from-a-leading-health-economist 8. Jeremias S. The biosimilar void: 90% of biologics coming off patent will lack biosimilars. The Center for Biosimilars. February 5, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars 9. Jeremias S. Biosimilars drive cost savings and achieve 53% market share across treatment areas. The Center for Biosimilars. January 16, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/biosimilars-drive-cost-savings-and-achieve-53-market-share-across-treatment-areas…
![Artwork](/static/images/128pixel.png)
1 S6 Ep41: The Top 5 Most-Listened to Podcasts of 2024 5:15
5:15
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai5:15![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Here are the top 5 episodes of Not So Different from 2024. Number 5: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved Number 4: Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars Number 3: Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report Number 2: Biosimilars in America: Overcoming Barriers and Maximizing Impact Number 1: Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024…
![Artwork](/static/images/128pixel.png)
1 S6 Ep40: Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition 5:47
5:47
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai5:47![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show Notes 1. Jeremias S. Skyrizi overtakes Humira: “product hopping” leaves biosimilar market in limbo. The Center for Biosimilars. November 7, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/skyrizi-overtakes-humira-product-hopping-leaves-biosimilar-market-in-limbo 2. Jeremias S. Celltrion sets sights on 2030 with expanded biosimilar portfolio, market reach. The Center for Biosimilars. November 6, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/celltrion-sets-sights-on-2030-with-expanded-biosimilar-portfolio-market-reach 3. Ferreri D. Making the cost of IBD care sustainable. The Center for Biosimilars. November 2, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/making-the-cost-of-ibd-care-sustainable 4. Ferreri D. Achieving PFS in advanced gastric cancer with HLX02 biosimilar, chemotherapy. The Center for Biosimilars. November 23, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/achieving-pfs-in-advanced-gastric-cancer-with-hlx02-biosimilar-chemotherapy 5. Ferreri D. Subcutaneous infliximab CT-P13 superior to placebo as maintenance therapy for IBD . The Center for Biosimilars. November 16, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/subcutaneous-infliximab-ct-p13-superior-to-placebo-as-maintenance-therapy-for-ibd 6. Ferreri D. Challenges, obstacles, and future directions for anti-TNF biosimilars in IBD. The Center for Biosimilars.November 9, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/challenges-obstacles-and-future-directions-for-anti-tnf-biosimilars-in-ibd 7. Jeremias S. Breaking down biosimilar barriers: the patent system.The Center for Biosimilars. November 11, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-the-patent-system 8. Jeremias S. Breaking down biosimilar barriers: payer and PBM policies. The Center for Biosimilars. November 13, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-payer-and-pbm-policies 9. Poore D. Breaking down biosimilar barriers: interchangeability. The Center for Biosimilars. November 14, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-interchangeability 10. The Center for Biosimilars Staff. Webinar: streamlining the regulatory process to advance access to biosimilars. The Center for Biosimilars. November 21, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/webinar-streamlining-the-regulatory-process-to-advance-access-to-biosimilars 11. Jeremias S. Can global policies to boost biosimilar adoption work in the US? The Center for Biosimilars. November 17, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/can-global-policies-to-boost-biosimilar-adoption-work-in-the-us -…
![Artwork](/static/images/128pixel.png)
1 S6 Ep39: Can Global Policies to Boost Biosimilar Adoption Work in the US? 21:49
21:49
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai21:49![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show notes To learn more about GBW, click here . To check out our coverage of the recent GRx+Biosims conference Craig mentioned, click here . To learn more about product hopping, click here . To read part 1 of our GBW series, click here . To read part 2 of our GBW series, click here . To read part 3 of our GBW series, click here . To hear another episode featuring more of Craig's thoughts on the Biden's administration's impact on the biosimilar industry, click here .…
![Artwork](/static/images/128pixel.png)
1 S6 Ep38: Biosimilars Development Roundup for October 2024—Podcast Edition 5:20
5:20
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai5:20![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show notes 1. Jeremias S. Strengthening the supply chain: key insights from FDA commissioner Dr Robert Califf. The Center for Biosimilars®. October 25, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/strengthening-the-supply-chain-key-insights-from-fda-commissioner-robert-califf 2. Jeremias S. FDA and industry experts unpack biosimilar device requirements. The Center for Biosimilars. October 23, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/fda-and-industry-experts-unpack-biosimilar-device-requirements 3. Jeremias S. Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims. The Center for Biosimilars. October 23, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/calling-for-unified-biosimilar-standards-stronger-education-at-grx-biosims 4. Jeremias S. Unifying standards: the need for streamlined biosimilar development. The Center for Biosimilars. October 22, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/unifying-standards-the-need-for-streamlined-biosimilar-development 5. Jeremias S. Enhancing Adoption of Infused Biosimilars for a Sustainable Future. The Center for Biosimilars. October 30, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/enhancing-adoption-of-infused-biosimilars-for-a-sustainable-future 6. Jeremias S. IQVIA webinar: enhancing regulatory strategies for biosimilars and generics. The Center for Biosimilars. October 14, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/iqvia-webinar-enhancing-regulatory-strategies-for-biosimilars-and-generics…
![Artwork](/static/images/128pixel.png)
1 S6 Ep37: Biosimilars Policy Roundup for September 2024—Podcast Edition 7:52
7:52
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai7:52![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show notes 1. FDA Approves Pavblu for Retinal Conditions 2. AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1 3. Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys 4. The Future of Biosimilar Gene Therapies: Key Issues and Potential 5. IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share 6. The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings 7. France Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD…
![Artwork](/static/images/128pixel.png)
1 S6 Ep36: Biosimilars Business Roundup for August 2024—Podcast Edition 5:22
5:22
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai5:22![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show notes 1. Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 2024 2. Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024 3. Formycon Reports €26.9 Million Revenue for First Half 2024, Driven by Biosimilars 4. CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel 5. FDA Approves Biosimilar Enzeevu for Eye Conditions 6. Manitoba Adopts Biosimilar Switching Policy 7. Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results 8. Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline…
![Artwork](/static/images/128pixel.png)
1 S6 Ep35: Biosimilars Policy Roundup for July 2024—Podcast Edition 5:12
5:12
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai5:12![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show notes 1. FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara 2. Ahzantive Receives FDA Approval as New Eylea Biosimilar 3. FDA Approves Epysqli as Second Soliris Biosimilar 4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed 5. Biosimilars and Employers: Strategies for Success 6. Learning the Lingo of Biologics and Biosimilars Is Critical 7. Singapore Experience Shows Benefits of Value-Driven Strategies in Generating Biosimilar Savings 8. Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch…
![Artwork](/static/images/128pixel.png)
1 S6 Ep34: Biosimilars in America: Overcoming Barriers and Maximizing Impact 27:23
27:23
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai27:23![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show notes To learn more about Cencora and their efforts, click here . To learn more about the Inflation Reduction Act's impact on biosimilars, click here .
![Artwork](/static/images/128pixel.png)
1 S6 Ep33: Biosimilars Oncology Roundup for June 2024—Podcast Edition 6:14
6:14
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai6:14![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show notes 1. Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships 2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology 3. EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions 4. New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers 5. ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars 6. ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars 7. Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability 8. Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity…
![Artwork](/static/images/128pixel.png)
1 S6 Ep32: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved 27:45
27:45
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai27:45![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
To learn more about the approval of denosumab-bddz, click here . To watch Curtis and Edgerton speak on the approval of denosumab-bddz and osteoporosis treatment, click here . To learn more about the ROSALIA study (NCT05405725), click here . Extra content: To read more about the Biosimilars Council position paper on how to improve biosimilar development, click here .…
![Artwork](/static/images/128pixel.png)
1 S6 Ep31: Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition 5:16
5:16
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai5:16![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show notes FDA Approves High-Concentration Cyltezo Eye on Pharma: Simlandi US Launch; Ranibizumab Partnership; Expanded Access for Adalimumab Biosimilars DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfentra Use Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD New Evidence Confirms Safe Biosimilar-to-Biosimilar Switching Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment…
![Artwork](/static/images/128pixel.png)
1 S6 Ep30: Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report 14:53
14:53
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai14:53![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show notes To read our coverage of the Cardinal Health report, click here . To read the full report, click here . To check out The Center for Biosimilars coverage of Festival of Biologics USA, click here .
![Artwork](/static/images/128pixel.png)
1 S6 Ep29: Biosimilars Policy Roundup for April 2024—Podcast Edition 5:07
5:07
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai5:07![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show notes FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar AON Saves Over $243 Million With High Biosimilar Adoption Julie Reed: Why 2024 Is Important for Biosimilars The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion Review Highlights Most Popular European Policies to Boost Biosimilar Uptake…
![Artwork](/static/images/128pixel.png)
1 S6 Ep28: Biosimilars Dermatology Roundup for March 2024—Podcast Edition 4:43
4:43
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai4:43![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Show notes AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake Adalimumab Expenditures in Countries With and Without Available Biosimilars Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5 Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More…
Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.